Welcome to our dedicated page for Jazz Pharmaceuticals Plc news (Ticker: JAZZ), a resource for investors and traders seeking the latest updates and insights on Jazz Pharmaceuticals Plc stock.
Jazz Pharmaceuticals Plc (NASDAQ: JAZZ) is a global biopharmaceutical leader developing life-changing therapies for complex conditions in oncology, neuroscience, and sleep medicine. This dedicated news hub provides investors and healthcare professionals with timely updates on corporate milestones, regulatory developments, and clinical research advancements.
Our curated collection features official press releases, earnings reports, and analysis of strategic initiatives. Users can track key updates including FDA regulatory decisions, clinical trial results, and therapeutic portfolio expansions. The resource prioritizes accuracy and comprehensiveness, serving as a primary source for understanding Jazz's market position.
Content spans multiple categories essential for informed decision-making: product approvals, research collaborations, financial performance, and manufacturing updates. Each entry maintains strict editorial standards to ensure relevance to both clinical and investment communities.
Bookmark this page for streamlined access to Jazz Pharmaceuticals' latest developments. Check regularly for updates on innovative therapies addressing narcolepsy, epilepsy, and hematologic malignancies, supported by the company's established R&D expertise.
Jazz Pharmaceuticals announced the publication of a Phase 3 study on Xywav, an oral solution for treating cataplexy and excessive daytime sleepiness in narcolepsy patients. The study demonstrated statistically significant improvements (p<0.0001) in the frequency of cataplexy attacks and Epworth Sleepiness Scale scores compared to placebo. Xywav has FDA approval and features a formulation with 92% less sodium than traditional treatments. Jazz plans to launch Xywav in Q4 2020, enhancing treatment options for narcolepsy patients.
Jazz Pharmaceuticals (Nasdaq: JAZZ) will host a webcast on October 26, 2020, at 4:30 p.m. EDT to discuss the commercial launch of Xywav™, approved by the FDA on July 21, 2020 for narcolepsy treatment. The solution will be available in early November. The presentation will include insights on sodium intake's effects on cardiovascular health and the evaluation of Xywav for idiopathic hypersomnia. The webcast can be accessed through Jazz Pharmaceuticals' website.
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) announced it will report its 2020 third quarter financial results on November 2, 2020, after market close. The company will host a live audio webcast at 4:30 p.m. EST to discuss these results and provide a business update. Interested parties can access the webcast via the Jazz Pharmaceuticals website. A replay will be available for one week.
Headquartered in Dublin, Jazz focuses on developing life-changing medicines in neuroscience and oncology.
Jazz Pharmaceuticals and PharmaMar will present new data for Zepzelca™ (lurbinectedin) at the IASLC 2020 North America Conference on Lung Cancer from October 16-17, 2020. The focus will be on outcomes from the Phase 2 basket trial in small cell lung cancer (SCLC), highlighting patients suitable for platinum re-challenge and those who demonstrated a response. Zepzelca is FDA-approved for metastatic SCLC after platinum-based chemotherapy. Continued approval may depend on further clinical validation.
On October 8, 2020, Jazz Pharmaceuticals announced positive top-line results from a Phase 3 study of Xywav (calcium, magnesium, potassium, sodium oxybates) in adults with idiopathic hypersomnia. The study showed significant improvements in excessive daytime sleepiness, with a p-value <0.0001 for key endpoints, including the Epworth Sleepiness Scale. There were no new safety concerns reported. Jazz plans to submit the data for FDA approval as a supplemental New Drug Application in early 2021, following the Fast Track designation granted in September 2020.
Jazz Pharmaceuticals (Nasdaq: JAZZ) has launched the Find the Right Fit program, aimed at educating patients about secondary acute myeloid leukemia (sAML) and myelodysplastic syndromes (MDS). Developed with the MDS Foundation and Cancer Support Community, this initiative provides valuable resources like articles, videos, and patient stories to help those newly diagnosed. The program emphasizes the criticality of education in managing treatment options for patients facing the challenges of sAML, which comprises about 30% of AML cases.
Jazz Pharmaceuticals (Nasdaq: JAZZ) has announced its partnership with the American Heart Association to improve sleep health through educational content. This initiative aims to combat the prevalent issue of inadequate sleep among Americans, which affects overall health and increases the risk of cardiometabolic diseases. Jazz's financial backing will support the development of multimedia resources, including podcasts dedicated to sleep disorders and their associated comorbidities. This collaboration aligns with Jazz's commitment to enhancing public health and well-being.
Jazz Pharmaceuticals has entered a new research collaboration with Redx Pharma to develop drug candidates targeting the Ras/Raf/MAPK cancer pathway. Jazz plans to pay Redx $10 million upfront and an additional $10 million in the second year, contingent on the ongoing research. Following the development of an IND-ready molecule, Redx could receive up to $200 million in milestone payments, along with royalties on future sales. This initiative strengthens Jazz's oncology pipeline as they strategically target cancer treatments.
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) announced participation in three virtual investor conferences. Morgan Stanley Global Healthcare Conference will be held on September 15, 2020, featuring CEO Bruce Cozadd. The Cantor Global Healthcare Conference follows on September 16, 2020, also with Cozadd. Lastly, the BofA Global Healthcare Conference on September 18, 2020 will have President Daniel Swisher presenting. Live webcasts will be accessible on the company website, with archives available for a week post-event.
Jazz Pharmaceuticals announced the presentation of 10 abstracts at Virtual SLEEP 2020, the annual meeting of the Associated Professional Sleep Societies, from August 28-30. These presentations showcase significant advancements in sleep medicine, particularly research related to Xywav™ (JZP-258), aimed at treating narcolepsy. Key highlights include studies on health-related quality of life and dose titration in narcolepsy patients. The event features ongoing research on innovative therapies for chronic sleep disorders, emphasizing Jazz's commitment to improving patient outcomes.
FAQ
What is the current stock price of Jazz Pharmaceuticals Plc (JAZZ)?
What is the market cap of Jazz Pharmaceuticals Plc (JAZZ)?
